Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Astrocytes implicated in preclinical AD

Astrocytes implicated in preclinical AD

Unlocking intrinsically disordered proteins: an interview with Peter Wright

Unlocking intrinsically disordered proteins: an interview with Peter Wright

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Study reveals how MGCs dispose waste that obstructs normal physiological processes

Study reveals how MGCs dispose waste that obstructs normal physiological processes

Brain ageing acceleration ‘nearly inevitable’ with age

Brain ageing acceleration ‘nearly inevitable’ with age

Researchers find molecular mechanism that may be responsible for development of amyloidoses

Researchers find molecular mechanism that may be responsible for development of amyloidoses

Approval to start trial of Videregen's replacement trachea technology

Approval to start trial of Videregen's replacement trachea technology

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

OSU discovery sheds new light on how proteins fold

OSU discovery sheds new light on how proteins fold

FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

Light-chain amyloidosis patients treated with high-dose chemo and stem cell transplantation have long-term survival

Light-chain amyloidosis patients treated with high-dose chemo and stem cell transplantation have long-term survival

Amyloid-beta kinetics reveal link between aging and AD risk

Amyloid-beta kinetics reveal link between aging and AD risk

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases